Stay updated with breaking news from Pharmaceutical Merger Task Force. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For years, the antitrust enforcement agencies have indicated their antipathy toward resolving competition issues in proposed mergers by entering into consent decrees that prohibit...
The Federal Trade Commission entered into a consent agreement with Amgen and Horizon Therapeutics, clearing the way for Amgen’s $28 billion acquisition of Horizon to go through. Announced on Sept. 1, Amgen agreed to not use its drug list to inhibit competition for Tepezza and Krystezza, which are Horizon’s biggest two drugs and the only